Analytical Data
-
Gene name
IL-27R beta
- Application
-
Alternative Names
DIRS1; FNDC6; IL-20R2; Fibronectin Type III Domain Containing 6
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
Q6UXL0
-
Expression Region
Ala37~Glu290
-
Molecular Weight
22/33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-27R beta, also known as WSX-1, is a critical receptor component of the interleukin-27 (IL-27) signaling pathway, which plays a significant role in regulating immune responses. IL-27 is a cytokine produced by antigen-presenting cells, primarily involved in promoting Th1 cell differentiation and modulating various immune functions. Research has indicated that IL-27R beta is pivotal for the biological activities of IL-27, including its anti-inflammatory effects and its influence on T cell fate, which makes this receptor a potential target for therapeutic interventions in autoimmune diseases and chronic inflammatory conditions. Moreover, studies suggest that IL-27R beta may also have implications in cancer immunotherapy, as IL-27 can enhance anti-tumor immunity. Understanding the structure and function of IL-27R beta, alongside the mechanisms of its signaling pathways, can provide insights into its role in the immune system and inform the development of novel treatments for immune-related disorders. The generation of recombinant IL-27R beta protein facilitates these studies, enabling researchers to explore its interactions and biological functions in vitro and in vivo, thus contributing to our knowledge of host defense mechanisms and disease pathogenesis. The increasing interest in IL-27 signaling underscores the importance of IL-27R beta as a subject of investigation for improving therapeutic strategies targeting immune modulation.
